Prior TNFi use (prespecified subgroup analysis)

Prior TNFi use (prespecified subgroup analysis)

Prespecified subgroup analysis: Improved efficacy vs. placebo regardless of previous TNFi treatment was observed1

In the TRUE NORTH study, the difference in clinical remission at 52 weeks between patients receiving ZEPOSIA and those receiving placebo was similar in TNFi-exposed patients and TNF-naïve patients1

Blue icon with arrows pointing outwards, representing a zoom optionPinch & zoom to explore

Adapted from Sandborn WJ et al. 2021.

The results for individual subgroups are not powered to draw meaningful conclusions and should therefore be interpreted with caution.
*Treatment difference (adjusted for stratification factors of clinical remission and concomitant corticosteroid use at Week 10).
†Defined by endoscopic improvement and histological remission.
‡Patients receiving placebo in the maintenance phase received ZEPOSIA during the induction phase.
ITT, intention-to-treat; TNFi, tumour necrosis factor inhibitor.

References

  1. Zeposia (ozanimod) Summary of Product Characteristics, 2022.

Legal Notice | Privacy Policy

Adverse events should be reported. Reporting forms and information can be found at: UK – www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Ireland-via HPRA Pharmacovigilance at www.hpra.ie Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (UK); 1800 749 749 (Ireland).

© 2022 Bristol-Myers Squibb Company. All rights reserved.
Job: 2084-GB-2300276 Date of Preparation: June 2023